From natural herbal wisdom to nano innovation: Revolutionizing tumor treatment through metabolic reprogramming

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189263 - 189263

Published: Jan. 1, 2025

Language: Английский

Synergistic Inhibition of Colon Cancer Cell Proliferation via p53, Bax, and Bcl-2 Modulation by Curcumin and Plumbagin Combination

ACS Omega, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Cancer is a major contributor to global morbidity and mortality. Among the different forms of cancer, colorectal cancer (CRC) third most frequently diagnosed in men second common type women globally. We aimed explore possible synergistic anticancer potential curcumin (Cur) plumbagin (PL) human colon cell line (HCT-116). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)/cytotoxicity assay revealed IC50 values 7.7 7.5 μM for Cur PL, respectively, as separate entity. However, combined treatment + PL significantly enhanced growth inhibitory compared with solitary treatments an value 6.8 μM. also led induction apoptosis by 41%, cycle arrest at G2/M phase, while Bax p53 genes were found be upregulated Bcl-2 gene was downregulated untreated/solvent control. Furthermore, elevated reactive oxygen species (ROS) production 59% resulted decline mitochondrial membrane (MMP) Catalase superoxide dismutase (SOD) activities reduced, leading lipid peroxidation (LPO) compromised integrity, which confirmed 4',6-diamidino-2-phenylindole (DAPI) propoidium iodide (PI) staining noted. Our vitro data further supported molecular docking, showed higher binding energy proteins (Bax, Bcl-2, p53) PL. Overall, our findings highlight potent effects combination, can exploited combination therapy CRC.

Language: Английский

ATM and p53 in aging and cancer: a double-edged sword in genomic integrity

Biogerontology, Journal Year: 2025, Volume and Issue: 26(3)

Published: May 5, 2025

Language: Английский